Skip to main content

Table 1 Demographics and characteristics of the participants

From: Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

Parameter

Gp1 (n = 58)

Gp2 (n = 81)

P-value

Age (years)

  

0.608

 Mean ± SD

51.02 ± 11.9

47.7 ± 14.1

 

 Median (range)

51 (24.0–72.0)

50 (20.0–76.0)

 

Sex, N (%)

 Female

24 (41.4)

39 (48.1)

1.000

 Male

34 (58.6)

42 (51.9)

Diabetes

15 (26.3)

14 (17.3)

0.200

Hypertension

12 (20.7)

12 (14.8)

1.000

Liver* N, %

 Abnormal echo pattern

26 (44.8)

44 (54.3)

 

 Cirrhotic

10 (17.2)

10 (12.3)

1.000

Viral load, copies/ml

1133597 (1363–1622326000)

633149 (99–1191861000)

0.228

ALT, IU/l

33.5 (6.3–136)

31.0 (3–121)

1.000

AST, IU/l

37.0 (7.0–139)

31.0 (9.4–122)

0.424

AFP, IU/L

3.5 (0.5–37)

4.1 (0.6– 39)

0.844

Albumin, g/dL

4.2 (2.8–5.1)

4.2 (2.9–5.9)

0.257

Total bilirubin, mg/dl

0.8 (0.3–4.5)

0.7 (0.1–2.9)

0.116

Indirect bilirubin, mg/dl

0.3 (0.1–2.1)

0.5 (0.1–1.6)

0.284

TSH, mIU/l

2.0 (1.0–3.1)

1.6 (0.9–2.3)

0.564

WBCs, 109 cells/l

5.5 (2.5–13.7)

6.3 (2.5–13.6)

0.264

HB (%)

13.6 (8–16.7)

13.8 (8–17)

1.000

Creatinine, mg/dl

0.8 (0.5–1.2)

0.9 (0.4–2)

1.000

Platelet, 109/l

192.5 (97–467)

203 (100–414)

1.000

HbA1c*, %

5.6 (3.5–9)

5.5 (4.0–9.0)

1.000

  1. Values are presented as mean ± SD, median (range), or number (%)
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, AFP alfa fetoprotein, TSH thyroid-stimulating hormone, WBCs white blood cells, HB hemoglobin, HBA1c glycated hemoglobin. P value ≤ 0.05 is considered significant
  3. Gp1 received sofosbuvir 400 mg/day plus daclatasvir 60 mg/day plus simeprevir 150 mg/day plus ribavirin 15 mg/kg/day for 12 weeks
  4. Gp2 received sofosbuvir 400 mg/day plus ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg/day plus RBV 15 mg/kg/day for 12 weeks